Project Grant R01AR085258
- The Hospital For Special Surgery Fund, Inc., doing business as HSS Foundation, received a $175,373 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research Federal Grant Program (CFDA 93.846). The award, effective July 1, 2025 through June 30, 2030, will support the development and validation of novel methods to identify antiphospholipid syndrome (APS) in large patient cohorts and...
- This Project Grant award of $139,895.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research into the link between inflammatory arthritis and the development of cardiovascular disease. The key objectives are to investigate whether "trained immunity" - the phenomenon where innate immune cells become reprogrammed to respond more efficiently to a...
- The $735,372 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research Program (CFDA 93.846) supports research to identify the key transcription factors and cytokine signals that regulate the expression of inflammatory chemokine receptors on T cells in chronic autoimmune conditions. The goal is to elucidate the dominant pathways controlling coordinated T cell migration to...
- The federal Project Grant award of $445,217 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research into the regulatory mechanisms of osteoclasts. Osteoclasts are cells primarily responsible for bone resorption, and their dysregulation is key to the pathophysiology of bone diseases such as osteoporosis, rheumatoid arthritis, and lytic bone metastasis. The...
- This federal Project Grant award of $172,584.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) is supporting a 5-year research career development program. The award recipient, The Trustees of Columbia University in the City of New York, will utilize multi-omics analyses to prioritize potentially causal genes associated with systemic sclerosis (SSc), a serious autoimmune...
- The federal Project Grant award of $649,391 provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) is supporting research to enhance healing after injury. The overarching objective is to define the mechanisms that restrain tissue regeneration in order to develop new therapeutics to improve healing of the gut and skin following injury or infection. The 5-year project, which...
- This $375,100 federal Project Grant award was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant funds a study to investigate the interplay between nucleic-acid-dependent phase separation and immune responses against cyclic GMP-AMP synthase (cGAS) in systemic lupus erythematosus (SLE). The research aims to determine how changes in the biophysical...
- This Project Grant award from the National Institute on Aging (NIA), under the Aging Research program (CFDA 93.866), provides $688,634.00 in funding to The Hospital For Special Surgery Fund, Inc. (dba HSS Foundation) from December 1, 2024 to November 30, 2029. The award supports research to investigate the mechanisms by which the constitutive type-I interferon (IFN-I) response suppresses osteoblastogenesis and bone formation, especially in the context of inflammatory conditions like rheumatoid...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $312,323 Project Grant to Knoubis Bio Inc. under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The grant supports the development of a novel bispecific biologic therapy for rheumatoid arthritis (RA) that targets the transmembrane tyrosine phosphatase PTPRS. The key activities under this Phase I project include conducting pharmacokinetic studies in mice...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research to characterize hematopoietic stem cell (HSC) impairment in a mouse model of systemic lupus erythematosus (SLE)-like disease. The $216,113 award to New York University School of Medicine will be used to test the hypothesis that SLE-like disease impairs HSC activity, potentially...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $267,423 to The Hospital For Special Surgery Fund, Inc. (doing business as HSS Foundation) to develop a biomarker using circulating cell-free tumor DNA (ctDNA) to assess the safety of immunosuppressive drugs used to treat inflammatory arthritis caused by immune checkpoint inhibitor (ICI) cancer treatments. The goal is to identify the safest approach to managing ICI-induced inflammatory arthritis without compromising cancer treatment. This 3-year project leverages a new ultra-sensitive whole genome sequencing and deep learning approach called MRD-EDGE that can detect extremely low levels of ctDNA, enabling tracking of cancer recurrence much earlier than standard imaging methods. The research aims to provide critical insights into balancing immunosuppressive therapies for ICI-induced inflammatory arthritis while maintaining effective cancer treatment.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $267.4k | 9/8/25 |